| Document |
Document Title |
|
WO/2024/074906A1 |
An anion exchange separation article is provided that is useful for separation of complex samples that contain a mixture of materials having different ionic charges. The separation articles include a plurality of polymeric chains grafted...
|
|
WO/2024/060373A1 |
Provided are a (+)-flurbiprofen salt derivative, a compound represented by the following formula (I), a method for preparing same, a pharmaceutical composition thereof, and use thereof.
|
|
WO/2024/033705A1 |
Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions...
|
|
WO/2024/003913A1 |
A process for the preparation of biguanidine compounds of formula (I) and triazine compounds of formula (IV); wherein R1, R2 and R3 are each independently hydrogen or an optionally substituted C1-C4 alkyl group, wherein the optional subs...
|
|
WO/2024/003915A1 |
A crystalline form of indaziflam, processes for the preparation thereof, an agrochemical composition containing the crystalline form of indaziflam and a process for the preparation of the agrochemical composition.
|
|
WO/2023/242101A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and/or genetic disorders. The present invention ...
|
|
WO/2023/241117A1 |
A synthesis method for an easily-soluble guanidinoacetic acid complex, comprising: first, adding guanidine hydrochloride into an alkaline solution A to generate free guanidine and obtain a solution B; then dropwise adding chloroacetic ac...
|
|
WO/2023/201712A1 |
The present invention provides a clofoctol derivative, which has a structure represented by general formula (1). The clofoctol derivative has high efficiency, low toxicity, wide antibacterial spectrum, fast sterilization speed, excellent...
|
|
WO/2023/183886A2 |
Disclosed herein are DMZ-derived compositions for and methods of modulating the expression and/or function of disease associated and/or diseasing causing secondary RNA structures and tertiary RNA structures.
|
|
WO/2023/180219A1 |
A method for synthesis of halide salts of the general formula: Zn+X- n; the method comprising reacting a first reactant being formate salt with a second reactant being a diatom halogen: X2.
|
|
WO/2023/123008A1 |
The present invention belongs to the field of biological medicine, and specifically relates to a biguanide derivative and the use thereof. The structural formula of the biguanide derivative of the present invention is as represented by f...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/061916A1 |
The present invention relates to the use of a composition containing guanidinoacetic acid during fattening of pigs with a low-energy feed in order to improve the energy utilisation of the feed by the pigs, wherein the low-energy feed dur...
|
|
WO/2023/060039A1 |
Described herein, inter alia, are alpha-5 beta-1 inhibitors, pharmaceutical compositions including alpha- 5 beta-1 inhibitors, methods for treating diseases using alpha- 5 beta-1 inhibitors, and processes for making alpha- 5 beta-1 inhib...
|
|
WO/2023/033016A1 |
Provided are: a guanidyl-protected arginine compound which, when used in a liquid-phase peptide synthesis reaction, renders satisfactory liquid-liquid separation possible; and a peptide synthesis method in which the guanidyl-protected ar...
|
|
WO/2023/033015A1 |
Provided is a method for producing a Fmoc-protected amino group-containing compound, wherein a raw material amino group-containing compound is not wasted, by-production of Fmoc-β-Ala-OH is suppressed, and the purification of a target su...
|
|
WO/2023/007399A1 |
The present disclosure provides compositions, methods of preparing, and method of use of a composition comprising: (a) about 0.05 wt% to about 10.0 wt% ethylenediamaminetetraacetic acid, a salt thereof, a chelating agent, or a combinatio...
|
|
WO/2023/003593A1 |
Compositions for pulmonary delivery comprising a biguanide or a pharmaceutically acceptable salt thereof in a form suitable to be aerosolized for pulmonary delivery to a human subject, and methods of treating lung disease.
|
|
WO/2023/287736A1 |
Pharmaceutical compositions of the invention comprise herteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.
|
|
WO/2023/278300A1 |
The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.
|
|
WO/2022/266753A1 |
There are provided conjugates of Formula (V) wherein R1 is a triantennary targeting moiety comprising N-acetyl galactosamine and R2 is a bioactive agent which is preferably an oligonucleotide, as well as pharmaceutical compositions and m...
|
|
WO/2022/261780A1 |
A method of diagnosing mild traumatic brain injury (mTBI) in a subject that includes measuring levels of a biomarker in a test sample; and comparing the levels of the biomarker in the test sample with a known normal reference level of th...
|
|
WO/2022/241978A1 |
The present invention belongs to the field of drug synthesis, and disclosed are a method for synthesizing metformin hydrochloride and an application thereof. The method for synthesizing comprises: after dissolving dicyandiamide and dimet...
|
|
WO/2022/237798A1 |
Provided in the present invention are a benzoylguanidine derivative, and a preparation method therefor and the use thereof. The benzoylguanidine derivative has a simple preparation method, has the effect of significantly inhibiting the a...
|
|
WO/2022/226924A1 |
A method for preparing a pigment filler for a composite material by using cyanamide waste residue comprises the following steps: carrying out pretreatment on cyanamide waste residue, wherein the pretreatment comprises pulping treatment a...
|
|
WO/2022/181695A1 |
The purpose of the present disclosure is to provide: a complex of a cell and a material; a method for producing a complex of a cell and a material; and a novel compound that can be used to obtain said complex. In a complex according to...
|
|
WO/2022/164150A1 |
Provided are a method for efficiently producing nafamostat mesylate using a simple process, and a method for producing 6-amidino-2-naphthol mesylate, which is an intermediate of nafamostat mesylate production, at high yield and under mil...
|
|
WO/2022/162604A1 |
The present invention relates to a novel cocrystal, a pharmaceutical composition comprising same and a preparation method therefor. By using the cocrystal of the present invention, cancers, inflammatory diseases, or viral infection disea...
|
|
WO/2022/148053A1 |
The present invention relates to the technical field of pharmaceutical preparations, and in particular to a purification method for metformin hydrochloride, a metformin hydrochloride sustained release tablet and a preparation method ther...
|
|
WO/2022/133586A1 |
Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction at low concentrations (~1 µM). The orphan nuclear receptor Nr4al (i.e. Nur77) is involved in the protective activity, which can be r...
|
|
WO/2022/106505A1 |
The present invention relates to compounds comprising two biguanidyl radicals that can be useful as anti-inflammatory agent, and also to new compounds comprising two biguanidyl radicals and their use as a drug, in particular for treating...
|
|
WO/2022/097813A1 |
The present invention relates to an eco-friendly and highly efficient method for preparing an ester compound based on an esterification reaction using a salt ion-exchange method, and an ester compound thereof. In conventional esterificat...
|
|
WO/2022/091065A1 |
In a cocrystal, a pharmaceutical composition comprising same, and a preparation method therefor, of the present invention, a novel cocrystal comprises niclosamide and nafamostat, or a pharmaceutically acceptable salt thereof. The novel c...
|
|
WO/2022/082859A1 |
Provided is a refining method for an amino acid or derivatives thereof, comprising: (1) preparing a saturated aqueous solution of an amino acid or derivatives thereof from a crude product of the amino acid or derivatives thereof at prese...
|
|
WO/2022/067043A1 |
The present invention includes a co-crystal of creatine and citric acid obtained by milling, methods of making the same that include a process for the preparation of co-amorphous formulation of creatine and citric acid, the process compr...
|
|
WO/2022/048909A1 |
The present invention concerns a modified method for preparing guanidine acetic acid (GAA) by reacting cyanamide with an excess molar amount of glycine in an aqueous reaction mixture in the presence of a base that avoids high molar amoun...
|
|
WO/2022/048913A1 |
The present invention refers to a method for preparing guanidino acetic acid by reacting cyanamide and glycine in an aqueous reaction mixture in the presence of a base, wherein the ammonia content in the reaction mixture is controlled to...
|
|
WO/2022/045163A1 |
The present invention provides a guanidine fatty acid salt production method through which liquid surface elevation, caused by carbon dioxide generated during production of guanidine fatty acid salt, can be suppressed. This guanidine fat...
|
|
WO/2022/027122A1 |
The present invention is related to compositions containing only natural products for the treatment of erectile and sexual dysfunction (ESD). More specifically relates to compositions containing Cannabis extract, and other herbal extract...
|
|
WO/2022/022448A1 |
The present invention belongs to the pharmaceutical field. Specifically, the present invention relates to a neuraminidase inhibitor compound as represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, or a ...
|
|
WO/2022/016288A1 |
Disclosed herein are cannabinoid salt compounds formed by mixing an acidic cannabinoid compound with a base. According to embodiments of the present disclosure, the base is selected at least for having a low toxicity. Also disclosed are ...
|
|
WO/2021/253087A1 |
The present invention relates to compounds of Formula I which form hydrogels upon mixing with water, and to fibers which form from the compounds. The hydrogels and fibers are antibacterial and not toxic towards mammalian cells. Such comp...
|
|
WO/2021/255552A1 |
Provided are amino acid based polymerizable compounds and their applications in ophthalmic devices. The amino acid based polymerizable compounds are of formula I: wherein R, R1, and R2 are as described herein.
|
|
WO/2021/250480A1 |
The present disclosure relates to a system for a composition for protein denaturation. The composition includes a non-nucleophilic denaturant comprising a substituted guanidine, wherein the denaturant has a pKa value greater than about 1...
|
|
WO/2021/245660A1 |
The present subject matter provides a composition for sampling body fluids and secretions, preserving nucleic acids, and disinfecting surfaces, the composition comprising: guanidinium thyocianate, sulfite salt, and at least one detergent...
|
|
WO/2021/246779A1 |
The present invention relates to an amide derivative synthesized using probenecid and arginine as reactants, a pharmaceutical composition comprising same for preventing, ameliorating, or treating heart failure, and a method for synthesiz...
|
|
WO/2021/227436A1 |
The present invention belongs to the technical field of medicine synthesis, relates to an antifungal compound, and in particular relates to an antifungal compound, a synthesis method and the use thereof, wherein the antifungal compound i...
|
|
WO/2021/211913A1 |
Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and/or preventing thromboembolism and bleeding or clotting d...
|
|
WO/2021/209345A1 |
The present invention provides derivatives of glutamine of formula (I) and derivatives of arginine of formula (II), and the use of such compounds as flavor modifiers. The invention further provides the use of such derivatives of glutamin...
|
|
WO/2021/184125A1 |
It is provided an anti-aging composition comprising at least one plant extract and a carrier, the at least one plant extract is at least one of Serenoa repens, Hypericum perforatum, Ilex paraguariensis, Ocimum tenuiflorum, Solidago virga...
|
